IP Library Granted Patent US 11,306,328
Granted Patent B2
US 11,306,328 · App. 14/319,498 · Granted Apr 19, 2022

Genome engineering

Inventors: George M. Church (Brookline, MA); Luhan Yang (Boston, MA); Marc Guell (Boston, MA); Joyce Lichi Yang (Cambridge, MA)
Assignee: President and Fellows of Harvard College
C12N15/907C12N5/0696C12N15/85C12N15/86C07H21/02C07H21/04C07K14/315C12N15/63C12N2510/00C12N2740/15043C12N2800/90C12N2830/003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,306,328
App. No.
14/319,498
Granted
Apr 19, 2022
Kind
B2
Abstract

Methods are provided for altering target DNA in a cell genetically modified to express a Cas 9 enzyme that forms a co-localization complex with a guide RNA complementary to the target DNA and that cleaves the target DNA in a site specific manner. Methods include introducing into the cell a first foreign nucleic acid encoding a donor nucleic acid sequence, introducing into the cell from media surrounding the cell the guide RNA complementary to the target DNA and which guides the Cas 9 enzyme to the target DNA, wherein the RNA and the enzyme are members of a co-localization complex for the target DNA, wherein the donor nucleic acid sequence is expressed, wherein the guide RNA and the Cas 9 enzyme co-localize to the target DNA, the Cas 9 enzyme cleaves the target DNA and the donor nucleic acid is inserted into the target DNA to produce altered DNA in the cell.

Claims (47)

1. A method of multiplex altering of a plurality of target DNA at multiple genomic loci in a eukaryotic cell in vitro wherein the cell genome is genetically modified to include a nucleic acid encoding a Cas 9 enzyme and wherein the Cas 9 enzyme is expressed, comprising

(a) introducing into the cell a DNA donor nucleic acid sequence,

(b) introducing into the cell a guide RNA complementary to the target DNA, wherein the guide RNA and the Cas 9 enzyme are members of a co-localization complex for the target DNA, wherein the guide RNA is in native form or is modified from native form to include a 5′ Cap structure or is modified from native form by treating with phosphatase,

wherein the guide RNA and the Cas 9 enzyme co-localize to the target DNA, the Cas 9 enzyme cleaves the target DNA and the donor nucleic acid is inserted into the target DNA to produce altered DNA in the cell, and

repeating steps (a) and (b) to result in multiple exogenous nucleic acid insertions in the cell wherein steps (a) and (b) are carried out without further introducing a nucleic acid encoding a Cas 9 enzyme.

2. The method of claim 1 wherein the guide RNA is between about 10 and about 500 nucleotides.

3. The method of claim 1 wherein the guide RNA is between about 20 and about 100 nucleotides.

4. The method of claim 1 wherein the RNA is a crRNA-tracrRNA fusion.

5. The method of claim 1 wherein the donor nucleic acid sequence is inserted by homologous recombination.

6. The method of claim 1 wherein the donor nucleic acid sequence is inserted by nonhomologous end joining.

7. The method of claim 1 further comprising in steps (a) and (b) introducing multiple donor nucleic acids and multiple guide RNAs to produce multiple alterations to the DNA in the cell.

8. The method of claim 1 wherein after producing altered DNA in the cell, the nucleic acid encoding the Cas 9 enzyme that forms a co-localization complex with the guide RNA complementary to the target DNA and that cleaves the target DNA in a site specific manner is removed from the cell genome.

9. The method of claim 1 wherein the guide RNA is physically attached to the donor nucleic acid sequence.

10. The method of claim 1 wherein the Cas9 enzyme is S. pyogenes Cas9.

11. The method of claim 1 wherein the eukaryotic cell is a human induced pluripotent stem cell.

12. The method of claim 1 wherein the guide RNA is about 100 nucleotides.

13. The method of claim 1 wherein the eukaryotic cell is a stem cell.

14. A method of multiplex altering of a plurality of target DNA at multiple genomic loci in a eukaryotic cell in vitro wherein the cell genome is genetically modified to include a nucleic acid encoding a Cas 9 enzyme and wherein the Cas 9 enzyme is expressed, comprising

(a) introducing into the cell a DNA donor nucleic acid sequence,

(b) introducing into the cell guide RNA complementary to the target DNA, wherein the guide RNA and the Cas 9 enzyme are members of a co-localization complex for the target DNA, wherein the guide RNA is modified from native form to include a 5′ Cap structure,

wherein the guide RNA and the Cas 9 enzyme co-localize to the target DNA, the Cas 9 enzyme cleaves the target DNA and the donor nucleic acid is inserted into the target DNA to produce altered DNA in the cell, and

repeating steps (a) and (b) to result in multiple exogenous nucleic acid insertions in the cell wherein steps (a) and (b) are carried out without further introducing a nucleic acid encoding a Cas 9 enzyme.

15. The method of claim 14 wherein the guide RNA is between about 10 and about 500 nucleotides.

16. The method of claim 14 wherein the guide RNA is between about 20 and about 100 nucleotides.

17. The method of claim 14 wherein the RNA is a crRNA-tracrRNA fusion.

18. The method of claim 14 wherein the donor nucleic acid sequence is inserted by homologous recombination.

19. The method of claim 14 wherein the donor nucleic acid sequence is inserted by nonhomologous end joining.

20. The method of claim 14 further comprising in steps (a) and (b) introducing multiple donor nucleic acids and multiple guide RNA to produce multiple alterations to the DNA in the cell.

21. The method of claim 14 wherein after producing altered DNA in the cell, the nucleic acid encoding the Cas 9 enzyme that forms a co-localization complex with the guide RNA complementary to the target DNA and that cleaves the target DNA in a site specific manner is removed from the cell genome.

22. The method of claim 14 wherein the guide RNA is physically attached to the donor nucleic acid sequence.

23. The method of claim 14 wherein the eukaryotic cell is a human induced pluripotent stem cell.

24. The method of claim 14 wherein the guide RNA is about 100 nucleotides.

25. The method of claim 14 wherein the eukaryotic cell is a stem cell.

26. A method of multiplex altering of a plurality of target DNA at multiple genomic loci in a eukaryotic cell in vitro wherein the cell genome is genetically modified to include a nucleic acid encoding a Cas 9 enzyme and wherein the Cas 9 enzyme is expressed, comprising

(a) introducing into the cell a DNA donor nucleic acid sequence,

(b) introducing into the cell guide RNA complementary to the target DNA, wherein the guide RNA and the Cas 9 enzyme are members of a co-localization complex for the target DNA, wherein the guide RNA is modified from native form by treating with phosphatase,

wherein the guide RNA and the Cas 9 enzyme co-localize to the target DNA, the Cas 9 enzyme cleaves the target DNA and the donor nucleic acid is inserted into the target DNA to produce altered DNA in the cell, and

repeating steps (a) and (b) to result in multiple exogenous nucleic acid insertions in the cell wherein steps (a) and (b) are carried out without further introducing a nucleic acid encoding a Cas 9 enzyme.

27. The method of claim 26 wherein the guide RNA is between about 10 and about 500 nucleotides.

28. The method of claim 26 wherein the guide RNA is between about 20 and about 100 nucleotides.

29. The method of claim 26 wherein the RNA is a crRNA-tracrRNA fusion.

30. The method of claim 26 further comprising in steps (a) and (b) introducing multiple donor nucleic acids and multiple guide RNA to produce multiple alterations to the DNA in the cell.

31. The method of claim 26 wherein after producing altered DNA in the cell, the nucleic acid encoding the Cas 9 enzyme that forms a co-localization complex with the guide RNA complementary to the target DNA and that cleaves the target DNA in a site specific manner is removed from the cell genome.

32. The method of claim 26 wherein the guide RNA is physically attached to the donor nucleic acid sequence.

33. The method of claim 26 wherein the eukaryotic cell is a human induced pluripotent stem cell.

34. The method of claim 26 wherein the guide RNA is about 100 nucleotides.

35. The method of claim 26 wherein the eukaryotic cell is a stem cell.

Assignments (2)
CONFIRMATORY LICENSE Recorded Oct 19, 2015
From: HARVARD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036897/0407 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2014
From: CHURCH, GEORGE M.; GUELL, MARC; YANG, JOYCE LICHI; YANG, LUHAN
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 034087/0773 →
Continuity (2)
Provisional Application 61858866 · Jul 26, 2013
Related Publication 20150031133A1 · Jan 29, 2015
Cited By (1)
US 12,251,429